Phase 1b APEX study: KSI-101 in patients with diabetic macular edema (DME) and macular edema secondary to inflammation (MESI) 64 • APEX is an ongoing, open label, multicenter platform study on the safety, tolerability, bioactivity, and pharmacokinetics of multiple intravitreal therapies in retinal diseases KSI-101 Multiple dose, dose-ranging study in 16 US sites Diabetic macular edema (first in human) Macular edema secondary to inflammation 41 patients treated (enrollment completed) 12 patients treated (enrollment completed) Preliminary results are being presented. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. APEX 10 patients have completed the Study 1 patient has discontinued treatment - Lost to follow-up 1 patient is ongoing 10 patients have completed the Study 2 patients have discontinued treatment - 1 adverse event (uveitis flare-up consistent with underlying disease) - 1 withdrew consent 29 patients are ongoing Preliminary data presented today